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Abstract 
The colon is a site where both local and systemic delivery of drugs can take place. 
Local delivery could, for example, allow topical treatment of inflammatory bowel 
disease. Treatment could be made more effective if it were possible for drugs to be 
targeted directly on the colon. Systemic side effects could also be reduced. Colon-
specific systems might also allow oral administration of peptide and protein drugs, 
which are normally inactivated in the upper parts of the gastrointestinal tract. 
Colon-specific systems could also be used in diseases that have diurnal rhythms. 
The aim of the work reported here was to develop a multiple-unit colon-specific 
formulation for administration by mouth, using enteric polymers as the relevant 
excipients. It was aimed to prepare a formulation that allows drug absorption after 
a lag time of about 4 hours. The idea was that the enteric polymers would prevent 
drug release and absorption in the upper gastrointestinal tract. Use of organic acids 
as additional excipients might further delay drug dissolution and absorption. 
Initially, enteric-coated matrix granules were made using Eudragit™ S100 to 
form matrices in granules and Aqoat™ AS-HF to provide an enteric coating. Citric 
acid, tartaric acid or succinic acid were incorporated in the granules to regulate pH. 
Enteric-coated matrix tablets were then made from the enteric-coated granules. 
Citric acid was used as a pH-regulating additive in both the granule cores and the 
tablet matrix. Ibuprofen and furosemide were used as model drugs. Drug 
dissolution was studied in vitro, at different pH levels. In vitro gradient dissolution 
studies were carried out in relation to some formulations. Drug absorption was 
studied in healthy volunteers by means of bioavailability tests.  
It was concluded that drug release and absorption can be targeted on the colon 
when enteric polymers and citric acid were used as excipients in multiple-unit 
tablets. Lag times of 2–4 hours in relation to commencement of drug absorption 
were noted when different amounts of citric acid were included in the tablet matrix 
and granules. It was found to be very important to include citric acid in the tablet 
matrix when preparing colon-specific formulations. Percentages of citric acid of 
between 10 and 15 are likely to be appropriate for colon-specific formulations with 
lag times of 3–4 hours. Inclusion of citric acid in granules is unnecessary. Citric 
acid in granules can retard drug release excessively. 
Correlations between in vitro and in vivo findings were poor. It is therefore 
important to conduct bioavailability tests at all stages of the process of 
development of new controlled-release dosage forms. Modifying circumstances 
during an in vitro gradient dissolution study may allow establishment of level-A in 
vitro/in vivo correlations. 
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11. Introduction 
During the last decade there has been interest in developing site-specific 
formulations for targeting drug delivery to the colon. The colon is a site 
where both local and systemic drug delivery can take place (Bussemeier et 
al. 2001). A local means of drug delivery could allow topical treatment of 
inflammatory bowel disease, e.g. ulcerative colitis or Crohn’s disease. Such 
inflammatory conditions are usually treated with glucocorticoids and 
sulphasalazine (Friend 1991, Watts and Illum 1997). Treatment might be 
more effective if the drug substances were targeted directly on the site of 
action in the colon. Lower doses might be adequate and, if so, systemic side 
effects might be reduced. A number of other serious diseases of the colon, 
e.g. colorectal cancer, might also be capable of being treated more 
effectively if drugs were targeted on the colon. 
Site-specific means of drug delivery could also allow oral administration 
of peptide and protein drugs, which normally become inactivated in the 
upper parts of the gastrointestinal tract (Watts and Illum 1997, Yang et al. 
2002). Vaccines, insulin and growth hormone are examples of candidates. 
However, the permeability of the epithelium of the colon to peptide and 
protein drugs is fairly poor, and bioavailabilities are usually very low. 
Colon-specific systems could also be used in conditions in which a 
diurnal rhythm is evident, e.g. asthma, rheumatic disease, ulcer disease and 
ischaemic heart disease (Yang et al. 2002). The incidence of asthmatic 
attacks is, for example, greatest during the early hours of the morning. 
Because dosage forms remain longer in the large intestine than in the small 
intestine, colon-specific formulations could be used to prolong drug 
delivery. 
22. Review of literature 
2.1. Colon-specific drug delivery systems 
Rectal administration offers the shortest route to targeting drugs on the 
colon. However, reaching the proximal part of the colon via rectal 
administration is difficult. Rectal administration can also be uncomfortable 
for the patient, and compliance may be less than optimal (Watts and Illum 
1997). 
There are several ways in which drugs can be targeted on the colon when 
they are given by mouth (Ashford and Fell 1993, Watts and Illum 1992, 
Yang et al. 2002). In time-dependent formulations the drug concerned is 
released during the period of gastrointestinal transit time. Release from 
formulations that contain pH-dependent polymers takes place on the basis 
that pH is higher in the terminal ileum and colon than in the upper parts of 
the gastrointestinal tract. The colon is also home to large numbers of 
bacteria of many kinds. Prodrugs and dosage forms from which drug release 
is triggered by the action of colonic bacterial enzymes have therefore been 
devised. 
2.1.1. Drug release based on variation of pH  
In the stomach pH ranges between 1 and 2 during fasting but increases after 
eating (Rubinstein 1995, Wilson et al. 1989b). The pH is about 6.5 in the 
proximal small intestine and about 7.5 in the distal small intestine (Evans et 
al. 1988). From the ileum to the colon pH declines significantly. It is about 
6.4 in the caecum. However, pH values as low as 5.7 have been measured in 
the ascending colon in healthy volunteers (Bussemer et al. 2001). The pH in 
the transverse colon is 6.6, in the descending colon 7.0.  
Use of pH-dependent polymers is based on these differences in pH 
levels. The polymers described as pH-dependent in colon specific drug 
delivery are insoluble at low pH levels but become increasingly soluble as 
pH rises (Ashford and Fell 1993). There are various problems with this 
approach, however. The pH in the gastrointestinal tract varies between and 
within individuals (Friend 1991, Ashford and Fell 1993, Kinget et al. 1998). 
3It is affected by diet and disease, for example (Rubinstein 1995). During 
acute stage of inflammatory bowel disease colonic pH has been has been 
found to be significantly lower than normal (Leopold and Eikener 2000). In 
ulcerative colitis pH values between 2.3 and 4.7 have been measured in the 
proximal parts of the colon (Fallingborg et al. 1989). Although a pH-
dependent polymer can protect a formulation in the stomach and proximal 
small intestine, it may start to dissolve even in the lower small intestine, and 
the site-specificity of formulations can be poor (Fukui et al. 2001). 
Contrariwise, failure of enteric-coated dosage forms, especially single-unit 
dosage forms, because of lack of disintegration has been reported (Bussemer 
et al. 2001). The decline in pH from the end of the small intestine to the 
colon can also result in problems. Lengthy lag times at the ileo-caecal 
junction or rapid transit through the ascending colon can also result in poor 
site-specificity of enteric-coated single-unit formulations (Ashford et al. 
1993a) 
Eudragit™ products are pH-dependent methacrylic acid polymers 
containing carboxyl groups. The number of esterified carboxyl groups 
affects the pH level at which dissolution takes place. Eudragit™ S is soluble 
above pH 7 and Eudragit™ L above pH 6. Eudragit™ S coatings protect 
well against drug liberation in the upper parts of the gastrointestinal tract 
and have been used in preparing colon-specific formulations (Dew et al. 
1982, Ashford et al. 1993a, Zahirul et al. 1999). When sites of disintegration 
of Eudragit™ S-coated single-unit tablets were investigated using a gamma 
camera they were found to lie between the ileum and splenic flexure. Site-
specificity of Eudragit S formulations, both single- and multiple-unit, is 
usually poor (Ashford et al. 1993a).   
Eudragit™ S coatings have been used to target the anti-inflammatory 
drug 5-aminosalicylic acid (5-ASA) in single-unit formulations on the large 
intestine (Dew et al. 1982, Kinget et al. 1998). Eudragit™ L coatings have 
been used in single-unit tablets to target 5-ASA on the colon in patients with 
ulcerative colitis or Crohn’s disease (Hardy et al. 1987).  
The polypeptide hormone vasopressin and insulin have been 
administered to rats orally in Eudragit™ S-coated single-unit capsules 
(Touitou and Rubinstein 1986, Rao and Ritchel 1992). Eudragit™ S-coated 
insulin capsules have also been administered orally to hyperglycaemic 
beagle dogs (Hosny et al. 2002). In the latter study it was concluded that 
4plasma glucose levels were lowered gradually and reproducibly but that 
delivery by means of the oral route was not bioequivalent to delivery by 
means of parenteral route (SC). 
Eudragit™ S has been used in combination with another methacrylic acid 
copolymer, Eudragit™ L100-55, in colon-targeted systems to regulate drug 
delivery (Khan et al. 1999). Dissolution studies showed that drug release 
profiles from enteric-coated single-unit tablets could be altered in vitro by 
changing the ratios of the polymers, in the pH range 5.5 to 7.0. 
Hydroxypropylmethylcellulose acetate succinate (HPMCAS) has been 
included in outer layers of single-unit press-coated tablets with a view to 
preventing drug release in the stomach and small intestine (Fukui et al. 
2001). In vitro dissolution studies suggested that such tablets could be 
useful as colon-specific formulations. No in vivo studies were undertaken. 
2.1.2. Drug release based on gastrointestinal transit 
time 
The time of transit through the small intestine is independent of formulation. 
It has been found that both large single-unit formulations and small 
multiple-unit formulations take three to four hours to pass through the small 
intestine (Davis et al. 1986, Parker et al. 1988, Wilson et al. 1989a, Adkin et 
al. 1993). Transit time through the small intestine is unaffected by particle 
size or density, or by the composition of meals. 
Because the time taken by formulations to leave the stomach varies 
greatly the time of arrival of a formulation in the colon cannot be accurately 
predicted. However, the effects of variation in gastric residence time can be 
minimized by using systems that are protected in the stomach, and drug 
release can be targeted on the colon by means of formulations that release 
the drug they contain a certain time after gastric emptying. Such 
formulations pass through the stomach and small intestine and drug is then 
released at the end of the small intestine or beginning of the colon (Kinget et 
al. 1998). Accordingly, formulations that depend for drug release on time of 
transit through the small intestine also usually depend for drug release on 
changes in pH in the gastrointestinal tract. Transit times through the colon 
that are faster than normal have been observed in patients with irritable 
bowel syndrome, diarrhoea and ulcerative colitis. Systems that depend on 
5gastrointestinal transit time for drug release are therefore not ideal for drug 
delivery in the colon for treatment of colon-related disease (Yang et al. 
2002). 
Combinations of hydrophilic (hydroxypropylmethylcellulose, HPMC) 
and hydrophobic polymers have been used as coatings for tablets that 
release drug from a core after a lag time (Pozzi et al. 1994). When the in 
vivo behaviour of such tablets was studied scintigraphically it was found 
that disintegration occurred in the proximal colon after about 5.5 hours 
(range 5 to 6.5 hours). Lag time could be adjusted by changing the thickness 
of the polymer layer. HPMC and hydroxypropylcellulose (HPC) have been 
used as swellable polymers in delayed release formulations (Gazzaniga et al. 
1994a, b, Vandelli et al. 1996). In such formulations enteric polymers can 
also be used as coatings to protect the formulation in the stomach. Using 
gammascintigraphy, Sangalli et al. (2001) investigated the in vivo behaviour 
of tablets with a drug-containing core coated with hydrophilic HPMC and 
an enteric polymer (Eudragit™ L30D). The lag-time in relation to 
absorption was found to be 7.3 ± 1.2 hours when the thickness of the 
polymer layer was greatest. The formulation disintegrated in the colon in all 
six volunteer subjects. 
Time-controlled formulations have also been prepared using water-
insoluble ethylcellulose and swellable polymer (HPC) (Hata et al. 1994, 
Takaya et al. 1995). Each of the formulations consisted of a core, drug, 
swelling agent and a water-insoluble membrane. The swelling agent HPC 
absorbed liquid and the ethylcellulose coat disintegrated as the core swelled. 
A lag time of 4.0 ± 0.5 hours in relation to absorption was found for this 
formulation in a human bioavailability study, and it was not influenced by 
food. 
A drug delivery system (Pulsincap™), from which there is rapid drug 
release after a lag-time, has been developed to allow release of drug in the 
large intestine (Wilding et al. 1991). The system involves an insoluble 
capsule body with a hydrogel plug. The plug is ejected from the capsule 
when it has swelled after a particular lag-time. A release profile is 
characterized by a period during which here is no release followed by rapid 
and complete drug release. Release using this system was found to be 
reproducible in vitro and in vivo. When gastrointestinal transit of the 
formulations was followed by means of gammascintigraphy it was found in 
6six of the eight subjects that the device reached the colon before drug was 
released (Wilding et al. 1992). The formulation had been administered with 
the subjects in a fasting state. Effects of food and gastric retention time were 
not investigated. In later scintigraphic studies it was found that the site of 
release of drug in the gastrointestinal tract varied. In one subject the 
formulation even remained in the stomach for a long time, and drug was 
also released in the stomach (Stevens et al. 2002).  
A formulation that involves a plug that erodes rather than a hydrogel plug 
has also been developed (Krögel and Bodmeier 1998). The aim of the 
studies descibed was to simplify the Pulsincap™ technology and develop a 
chronopharmaceutical formulation (Ross et al. 2000). 
2.1.3. Drug release based on the presence of colonic 
microflora 
Both anaerobic and aerobic micro-organisms inhabit the human 
gastrointestinal tract (Rubinstein 1990, Watts and Illum 1997, Kinget et al. 
1998). In the small intestine the microflora is mainly aerobic, but in the 
large intestine it is anaerobic. About 400 bacterial species have been found 
in the colon, and some fungi. Most bacteria inhabit in the proximal areas of 
the large intestine, where energy sources are greatest (Watts and Illum 
1997). Carbohydrates arriving from the small intestine form the main source 
of nourishment for bacteria in the colon. The carbohydrates are split into 
short-chain fatty acids, carbon dioxide and other products by the enzymes 
glycosidase and polysaccharidase. Protease activity in the colon can result in 
cleavage of proteins and peptides. In the proximal colon the pH is lower 
than at the end of the small bowel because of the presence of short-chain 
fatty acids and other fermentation products. Diet can affect colonic pH 
(Rubinstein 1990, Watts and Illum 1997, Kinget et al. 1998). 
The presence of colonic microflora has formed a basis for development 
of colon-specific drug delivery systems. Interest has focused primarily on 
azo reduction and hydrolysis of glycoside bonds. However, the colonic 
microflora varies substantially between and within individuals, reflecting 
diet, age and disease. Such variations need to be taken into account in 
developing colon-specific formulations depending on the presence of 
colonic microflora. There is also significant proteolytic activity in the colon, 
7although this is 20 to 60 times less than in the small bowel (Rubinstein et al. 
1993, Watts and Illum 1997). Even when proteolytic activity is relatively 
low a drug may remain much longer in the colon than in the small intestine, 
with the result that it is exposed longer to proteolytic activity (Bussemer et 
al. 2001).  
Prodrugs have been used in targeting drugs on the large intestine. 
Sulphasalazine, used in the treatment of ulcerative colitis and Crohn’s 
disease, is a colon-specific prodrug (Friend 1991, Watts and Illum 1997, 
Kinget et al. 1998). In the colon sulphasalazine is split by bacterial azo-
reduction into 5-ASA and sulphapyridine (Klotz 1985). Sulphapyridine can 
cause side effects, and other carriers for delivery of 5-ASA to the colon 
have therefore also been investigated. Olsalatzine consists of two molecules 
of 5-ASA linked by an azo-bond. Ipsalatsine and balsalatsine are other 5-
ASA containing prodrugs (Friend 1991). Polymers and polyamides 
containing azo groups have been used to convey 5-ASA to the large 
intestine (Schacht et al. 1996). Azo polymers have been used as colon-
specific film coatings (Saffran et al. 1986, Van den Mooter et al. 1992). 
Colon targeting by means of azo polymers is associated with many 
problems (Van den Mooter et al. 1997). Microbial degradation of azo 
polymers is usually slow, and drug delivery can be incomplete and irregular.  
Not enough is yet known about the safety of azo polymers. In vivo 
absorption studies with azo polymers have mostly been carried out using 
rats. No results of studies in human beings are available. Although the 
gastrointestinal microflora of rats and humans differ, results of in vivo 
experiments with rats can give some indications regarding biodegradation of 
azo polymers (Van den Mooter 1992).  
Hydrogels containing azo-aromatic cross-links have been investigated in 
connection with site-specific drug delivery of peptide and protein drugs 
(Brønstedt and KopeMek 1992, KopeMek et al. 1992). In the low pH range of 
the stomach the gels have a low equilibrium degree of swelling and the drug 
is protected against digestion by enzymes, but at high pH levels they swell. 
So in the stomach a drug will be protected, but released in the colon, where 
cross-links become degraded. 
 The colonic microflora produces a wide range of glycosidases capable of 
hydrolysing glycosides and polysaccharides (Friend and Tozer 1992). 
Glycosides of glucocorticosteroids have been synthesized, and tested in 
8rodents. The problem in these studies was that some drug was hydrolysed 
even in the small intestine. However, in rodent bacterial glycosidase activity 
in the small intestine is some 100 times greater than in human beings. It is 
likely that drug delivery in man would be more predictable than in rodents. 
Glucuronides, which are less subject to hydrolysis in the small intestine than 
glycosides, have also been used as drug carriers (Friend 1995).   
An extensive range of drug delivery systems based on polysaccharides 
has been investigated. The advantage of these materials is that most are 
easily available. Disadvantages are that most of polysaccharides are 
hydrophilic and gel forming (Watts and Illum 1997). In preparing dosage 
forms from polysaccharides it is necessary to ensure that no drug is released 
until it reaches the colon.  
Amylose has been used in coatings of colon-specific formulations  
(Milojevic et al. 1996a, b). Amylose, a major component of starch, swells 
too much on its own, but amylose-ethylcellulose coatings have been 
investigated in connection with targeting of drug release on the colon. From 
the results of in vitro studies it was concluded that amylose-ethylcellulose 
coatings could be suitable for colon-specific formulations.  
Pectin is a polysaccharide, found in the cell walls of plants. It is totally 
degraded by colonic bacteria but is not digested in the upper gastrointestinal 
tract (Ashford et al. 1994, Rubinstein et al. 1993). One disadvantage of 
pectin is its solubility. This can however be adjusted by changing its degree 
of methoxylation, or by preparing calcium pectinate (Rubinstein et al. 1993, 
Ashford et al. 1994). The film-coating properties of pectin have been 
improved through use of ethylcellulose (Wakerly et al. 1996). Pectin has 
also been used with chitosan (Munjeri et al. 1997) and HMPC (Turkoglu et 
al. 1999). It has been shown in studies in which gamma camera was used 
that pectin-coated tablets disintegrate in the colon during transit (Ashford et 
al. 1994).  
Cross-linked guar gum has been used as a drug carrier in matrix tablets 
(Gliko-Kabir et al. 1998, Rama Prasad et al. 1998). It was concluded that 
guar gum is suitable for preparation of colon-specific formulations and is 
particularly suitable as a carrier of drugs that are not very soluble in water. 
However, the guar gum formulations mentioned have only formed the 
subjects of in vitro dissolution studies and in vivo evaluation in rats. 
9Dextran ester prodrugs have been investigated as means of transporting 
drugs to the colon (Harboe et al. 1989, McLeod et al. 1993). When the 
bioavailability of naproxen after administration of dextran-naproxen 
prodrug was assessed in pigs, lag times of two to three hours were observed. 
Dextran esters of fatty acids have been used to form colon-specific film 
coatings (Bauer and Kesselhut 1995). The suitability of such formulations 
for colon-specific drug delivery in human being remains to be demonstrated 
in volunteers. 
Chitosan is a high-molecular-weight polysaccharide that is degraded by 
colonic microflora (Tozaki et al. 1997). Insulin and 5-ASA have been 
administered to rats in enteric-coated chitosan capsules. A multiple-unit 
formulation containing chitosan and drug has also been prepared (Lorenzo-
Lamosa et al. 1998). This formulation depended for drug delivery on both 
variations in gastrointestinal pH and the presence of colonic microflora. 
2.1.4. Pressure-controlled drug-delivery systems 
As a result of peristalsis, higher pressures are encountered in the colon than 
in the small intestine. Takaya et al. (1995) have developed pressure-
controlled colon-delivery capsules prepared using an ethylcellulose, which 
is insoluble in water. In such systems drug release occurs following 
disintegration of a water-insoluble polymer capsule as a result of pressure in 
the lumen of the colon. The thickness of the ethylcellulose membrane is the 
most important factor for disintegration of the formulation (Muraoka et al. 
1998, Jeong et al. 2001). The system also appeared to depend on capsule 
size. When salivary secretion of caffeine after oral administration of 
pressure-controlled capsules was studied in human volunteers, a correlation 
was found between ethylcellulose membrane thickness and the time of first 
appearance of caffeine in the saliva (Muraoka et al. 1998). 
Because of reabsorption of water from the colon, the viscosity of luminal 
content is higher in the colon than in the small intestine. It has therefore 
been concluded that drug dissolution in the colon could present a problem in 
relation to colon-specific oral drug delivery systems (Takaya et al. 1998). In 
pressure-controlled ethylcellulose single-unit capsules the drug is in a 
liquid. Lag times of three to five hours in relation to drug absorption were 
noted when pressure-controlled capsules were administered to human 
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subjects (Hu et al. 2000). It was concluded that the capsules disintegrated in 
the colon because of increases in pressure. It was also concluded that the 
formulation studied was advantageous in that the drug release mechanism is 
independent of pH (Hu et al. 1999). The site at which the formulations 
disintegrated was not demonstrated in the studies mentioned above. The 
mechanism of disintegration was also not clarified. As discussed above, 
ethylcellulose coatings have also been used in connection with time-
controlled drug delivery. Disintegration of the formulation can therefore 
also occur some time after administration, even in the small intestine. 
2.1.5. Conclusions concerning colon-specific drug-
delivery methods 
During the last decade many investigations have been carried out with the 
aim of discovering an ideal formulation for colon-specific drug delivery. 
Many approaches have been demonstrated. All have some disadvantages 
(Table 1). 
The microflora of the colon can split polymers. However, such enzymatic 
degradation is usually excessively slow. The bioavailabilities of drugs from 
such formulations can be low. In addition, little is known about the safety of 
the polymers and few have been accepted for use in relation to medicines.  
Most studies relating to biodegradable polymers have been carried out only 
in vitro or in laboratory animals.  
Time-controlled formulations have also been investigated and developed 
in connection with targeting of drug delivery on the colon. Formulations of 
this kind need to be manufactured in such a way that they remain intact in 
the stomach, in the presence or absence of food. Manufacture of such 
formulations on an industrial scale is often complicated and expensive. 
Formulations involving enteric polymers that react to changes in 
gastrointestinal pH have been extensively used in connection with colon-
specific drug delivery. Enteric polymers have been shown to be safe, and 
have been accepted for use in drug products. The enteric polymers that have 
been used are soluble above pH 6 to 7. The pH at the end of the small 
intestine is about 7.5. It is therefore obvious that drug release from enteric-
coated formulations can begin from the end of the small intestine. pH levels  
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Table 1. Advantages and disadvantages of various oral colon-specific drug 
delivery methods. 
Method Advantages Disadvantages References 
Time-dependent 
systems 
Small intestine 
transit time fairly 
consistenta
Substantial 
variation in 
gastric retention 
timesb
Transit through 
the colon more 
rapid than 
normal in 
patients with 
colon diseasec
Davis et al. 
1986a
Yang et al. 
2002b,c 
Ashford and Fell 
1993b
Watts and Illum 
1997b
pH-dependent 
systems 
Formulation well 
protected in the 
stomachd
pH levels in the 
small intestine 
and colon vary 
between and 
within 
individualse
pH levels in the 
end of small 
intestine and 
caecum are 
similarf
Poor site 
specificityg
Friend 1991d
Ashford and Fell 
1993 d,e 
Kinget et al. 
1998 d,e,f 
Yang et al.    
2002 e,f 
Ashford et al. 
1993b g 
Microflora-
activated systems
Good site-
specificity with 
prodrugs and 
polysaccharidesh
Diet and disease 
can affect 
colonic 
microflorai
Enzymatic 
degradation may 
be excessively 
slowj
Few have been 
accepted for use 
in relation to 
medicinesk
Rubinstein et al. 
1997 h,i 
Yang et al. 2002 j
12
also decline from the ileum to the colon. If an enteric-coated formulation is 
still intact after passage through the small intestine there may be a significant 
delay in relation to drug release in the colon, where the pH value is lower. 
Rapid drug release in the ascending colon is however usually required when 
colon-specific formulations are used, e.g. in treating colon disease. It is 
advantageous if drug release from a formulation can begin immediately 
after it enters the colon, even though drug release may subsequently be 
retarded. 
It may be concluded that no ideal formulation for colon-specific drug 
deliver yet exists. Drug release from an ideal formulation should begin in 
the ascending colon, at a predetermined rate. The manufacturing process for 
the formulation should also be simple and not too expensive. 
2.2. In vitro and in vivo evaluation of colon-
specific drug-delivery systems 
In vitro dissolution testing is important in the development of solid dosage 
forms. The method used should simulate the environment to which the 
dosage form being developed will be exposed in the gastrointestinal tract. In 
the United States Pharmacopoeia (USP) dissolution procedures are 
described for conventional oral formulations, and for extended-release and 
delayed-release formulations (USP 23). In the case of enteric-coated 
formulations the test for ”delayed-release articles” should be used. 
However, controlled-release formulations used for colon-specific drug 
delivery are usually complex, and the dissolution methods described in the 
USP cannot wholly mimic in vivo conditions such as those relating to pH, 
bacterial environment and mixing forces (Yang et al. 2002). 
The conventional method involving dissolution in various buffers is 
useful for assessing the ability of an enteric-coating to prevent drug release 
in the stomach and small intestine. Dissolution studies of this kind can be 
used in relation to both time-release systems and formulations with enteric-
coatings. 
Dissolution tests relating to colon-specific drug delivery systems may be 
carried out using the conventional basket method. Parallel dissolution 
studies in different buffers may be undertaken to characterize the behaviour 
of formulations at different pH levels. Rudolph et al. (2001) carried out 
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dissolution tests of a colon-specific formulation in various media simulating  
pH conditions at various locations in the gastrointestinal tract. The media 
chosen were, for example, pH 1.2 to simulate gastric fluid, pH 6.8 to 
simulate the jejunal region of the small intestine, and pH 7.2 to simulate the 
ileal segment.  
Consecutive dissolution tests in different buffers for different periods of 
time best simulate the transit of a formulation through the gastrointestinal 
tract. In gradient dissolution studies a particular formulation unit is exposed 
to buffers representing successive conditions in the gastrointestinal tract. 
Enteric-coated capsules for colon-specific drug delivery have been 
investigated in a gradient dissolution study in three buffers. The capsules 
were tested for two hours at pH 1.2, then one hour at pH 6.8, and finally at 
pH 7.4 (Cole et al. 2002). The relationship between percentage of drug 
released in vitro and percentage of drug absorbed in vivo was observed 
when pulsatile-release tablets were tested in vitro for two hours at pH 1.2 
followed by a dissolution study at pH 6.8 (Fan et al. 2001). 
Fukui et al. (2000) kept enteric-coated tablets in a buffer at pH 1.2 for 16 
hours. A dissolution study was then carried out at pH 6.8. It was concluded 
that the dissolution profiles of formulations that had not been kept in buffer 
at pH 1.2 did not differ markedly from dissolution profiles of formulations 
that had been kept in buffer at pH 1.2. Exposure to acid in the stomach 
should therefore not affect the dissolution properties of such formulations in 
the lower gastrointestinal tract. On the basis of these findings it is obvious 
that sufficient information regarding dissolution properties of formulations 
can often be obtained using parallel dissolution tests. Gradient dissolution 
tests are usually unnecessary. 
To allow the performance of colon-specific delivery systems containing 
biodegradable polymers to be assessed, the contents of animal caecum have 
been used in dissolution studies (Yang et al. 2002). Such studies provide no 
information about the physical and chemical functionality of a system. 
In vivo bioavailability tests in human beings are important in developing 
controlled-release drug delivery systems. From of the results of 
bioavailability tests, sites of drug liberation in vivo can be determined, if the 
formulation has been administered to the subjects in the fasting state. 
However, it is impossible to predict times of arrival of formulations in the 
colon accurately, because gastric emptying times vary so greatly. In recent 
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years gammascintigraphy has become the most popular means of 
investigating the gastrointestinal performance of pharmaceutical dosage 
forms, especially site-specific dosage forms (Wilding et al. 1991). By means 
of gammascintigraphic imaging, information can, for example, be obtained 
regarding time of arrival of a colon-specific drug delivery system in the 
colon, times of transit through the stomach and small intestine, and 
disintegration. Information about the spreading or dispersion of a 
formulation and the site at which release from it takes place can also be 
obtained (Hebden et al. 1999). Gammascintigraphic studies can also provide 
information about regional permeability in the colon. Information about 
gastrointestinal transit and the release behaviour of dosage forms can be 
obtained by combining pharmacokinetic studies and gammascintigraphic 
studies (pharmacoscintigraphy). Good correlations between appearance of a 
drug in plasma and observed disintegration times have been recorded. 
When gammascintigraphy was used to investigate the suitability of an 
Eudragit™ S-coated tablet for drug delivery to the colon results of the study 
were found to be in accordance with results of in vitro dissolution studies 
(Ashford et al. 1993a). Gammascintigraphy has also been used to determine 
gastrointestinal transit times and sites of disintegration of calcium pectinate 
tablets intended to allow colon-specific drug delivery (Adkin et al. 1997). 
Although the tablets disintegrated completely in the colon it was concluded 
that gammascintigraphy did not allow exact information about the 
mechanism of disintegration to be obtained.  
Many pharmacoscintigraphic studies have been reported. Stevens et al. 
(2002) used gammascintigraphy to identify the site of release from a 
Pulsincap™ formulation, intended to release drug after a five-hour lag time. 
Plasma concentrations of the model drug were also followed. A good 
correlation was found between release times determined scintigraphically 
and pharmacokinetic profiles. A correlation between pharmacokinetic and 
gammascintigraphic data was also found when times and anatomical 
locations of break-up of colon-specific formulation were determined by 
Sangalli et al. (2001). 
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3. Aim of study 
As discussed earlier enteric polymers have been widely used to form films 
in connection with formulations intended to target drug delivery on the 
colon. Site-specificity of such formulations has, however, usually been poor. 
In the present study it was therefore decided to determine whether better 
formulations for colon-specific drug delivery could be prepared using 
enteric polymers to form matrices as well as films. Most formulations 
previously studied have been single-unit formulations. A secondary aim of 
the work described here was therefore also to evaluate whether multiple-unit 
colon-specific formulations has advantages. 
In our work we also tried to improve site-specificity in relation to the 
colon through use of organic acids as excipients. Incorporation of organic 
acids was intended to delay dissolution of enteric polymers by keeping the 
pH level within formulations low, even where the pH in the gastrointestinal 
tract exceeded 7. It was hoped that it would be possible to prevent drug 
liberation and absorption in the terminal ileum and defer commencement of 
drug absorption until the proximal colon was reached.  
In the dosage forms studied enteric polymers were used at three stages 
(Fig. 1). Firstly, we prepared matrix granules in which enteric polymers 
were used as both binders and film coatings. Enteric-coated multiple-unit 
tablets were then prepared, using the granules just mentioned and various 
excipients. Organic acids were used as excipients in both the granules and 
tablet matrices with the aim of delaying disintegration of the formulations 
and drug liberation. The granules that make up the individual units in 
multiple-unit systems of the kind we studied can become widely 
disseminated over the surface of the colon, an advantage in formulations 
intended to act locally in the colon, i.e. to be colon-specific. 
Ibuprofen and furosemide were used as model drugs because they are 
absorbed at different sites in the human gastrointestinal tract. Ibuprofen is 
well absorbed throughout the latter (Wilson et al. 1989a). In contrast, 
furosemide is well absorbed only in the stomach and at the beginning of the 
small intestine (Ritschell et al. 1991). Its absorption in the colon is 
negligible and it is therefore suitable for use as an unabsorbed model drug. 
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The elimination half-life of each model drug is brief, about 2 hours 
(Ritschell 1992). In studies of effects of formulation on drug absorption a 
brief elimination half-life is beneficial. At the outset of the study five enteric 
polymers (Eudragit™ S, Eudragit™ L, Aqoat™ AS-HF, Aqoat™ AS-MF, 
Aquateric™), dissolving at different pH levels, were used to modify drug 
delivery. Succinic acid, tartaric acid and citric acid were used as pH-
regulating additives. 
Dissolution studies at different pH levels were conducted throughout the 
study. Conclusions were drawn primarily from results of in vivo 
bioavailability tests with ibuprofen. One of the most important 
pharmacokinetic parameters calculated was lag time in relation to 
commencement of drug absorption. For a colon-specific formulation the lag 
time should be 4–5 hours with subjects in the fasted state. Amounts of drug 
liberated and absorbed were calculated from area under concentration time 
curve (AUC) values. Determination of tmax (time to peak concentration) and 
Cmax (maximum plasma concentration) values allowed evaluation of 
whether absorption of ibuprofen was delayed or retarded. 
The type of formulation we studied has not been described before. 
Although the formulations are moderately complex, their manufacture is 
easy, and might also be undertaken on an industrial scale. 
 
Figure 1. Structure of multiple-unit colon-specific tablet developed. 
 
FILM COATING 
- enteric polymer FILM COATING
- enteric polymer 
TABLET MATRIX 
- microcrystalline cellulose 
- organic acid 
 
GRANULE CORE 
- model drug 
- organic acid 
- enteric polymer  
- diluent 
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In detail, the aims of the study described here were as set out below: 
 
The primary aim was to prepare matrix granules incorporating model 
drugs and diluents, using enteric polymers as binders, and to 
determine whether drug dissolution and commencement of drug 
absorption can be influenced in this way. The variables studied were 
the model drug, the dissolution pH of the enteric polymer and the 
nature of the diluent (I). 
 
Secondarily it was determined whether drug dissolution and 
absorption could be further delayed through use of various enteric 
polymers to form films in matrix granules. The effect of the 
thickness of enteric coating was in particular investigated (I). 
 
In a third phase of the study an organic acid was incorporated in 
uncoated and enteric-coated granules to determine whether 
disintegration of the granules and, consequently, drug liberation 
could be delayed by doing so. The variables studied during that 
phase were the nature and amount of organic acid (II). 
 
Enteric-coated multiple-unit tablets were then prepared from the 
enteric-coated granules that gave the best results. The effect of 
inclusion of organic acid in the tablet matrix was also investigated. It 
was assumed that drug release from multiple-unit formulations 
containing two types of enteric coating and an organic acid as 
excipient might be sufficiently delayed for drug delivery to be colon-
specific. The optimal distribution of the organic acid between the 
granules and the tablet matrix was determined (III, IV). 
 
In vitro/in vivo correlations between dissolution and bioavailability 
parameters were determined, to see whether the in vivo behaviour of 
formulations might be predictable from results of dissolution studies. 
If so, it might be possible to reduce numbers of bioavailability 
studies in healthy volunteers, and accelerate the drug-development 
process. 
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4. Materials and methods 
4.1. Model drugs (I–IV) 
Ibuprofen (Ph. Eur.) was used as a model drug in matrix granules and in 
multiple-unit tablets (I–IV). Furosemide (Ph. Eur.) was used as a model 
drug in matrix granules (I). 
Ibuprofen (2-(-4-isobutylphenyl)-propionic acid) is almost insoluble in 
water. Its pKa is 5.3 (Herzfeldt and Kümmel 1983). Ibuprofen is well 
absorbed throughout the gastrointestinal tract and is therefore suitable as a 
model drug in relation to study of colon-specific formulations (Wilson et al. 
1989a). The elimination half-life of ibuprofen is about 2 hours. Therapeutic 
concentrations in plasma range from 5 to 50 mg/l (Ritschell 1992). 
Ibuprofen has anti-inflammatory, antipyretic and analgesic properties. 
Furosemide (4-chloro-N-furfuryl-5-sulfamoylanthranilic acid) is almost 
insoluble in water. Its pKa is 3.9. Furosemide is well absorbed in the 
stomach (Ritschell et al. 1991). Small amounts can be absorbed in the small 
intestine. Absorption in the large intestine is negligible. It is therefore 
suitable for use as an unabsorbed model drug in studying colon-specific 
formulations. The elimination half-life of furosemide is 1.5 hours. 
Therapeutic concentrations in plasma range from 0.1 to 0.3 mg/l (Ritschell 
1992). Furosemide is a potent diuretic. It acts primarily by inhibiting 
electrolyte absorption in the loop of Henle. 
4.2. Enteric polymers (I–IV) 
The enteric polymers used were the methacrylate copolymers Eudragit™ S 
and Eudragit™ L (Röhm Pharma, Germany), the hydroxypropyl 
methylcellulose acetate succinates, Aqoat™ AS-HF and Aqoat™ AS-MF 
(Shin-Etsu Chemical Co., Japan) and cellulose acetate phthalate 
Aquateric™ (FMC Corporation, USA). The enteric polymers used dissolve 
around or below pH 7 (Peeters and Kinget 1993, Bauer and Kesselhut 1995), 
cellulose acetate phthalate at pH 6.2, Eudragit™ L at pH 6 and Eudragit™ S 
and Aqoat™ AS-HF at pH 7. 
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4.3. Pharmaceutical additives (I–IV) 
Calcium phosphate (CaHPO4·2H20), lactose (Ph. Eur), mannitol (Ph. Eur.) 
and microcrystalline cellulose (Avicel™ PH 102) were also incorporated in 
the granules. Succinic acid (Ph. Eur.), tartaric acid (Ph. Eur.) or citric acid 
(monohydrate, Ph. Eur.) were used in granules to adjust the pH of their 
microenvironments. Citric acid was also used as a pH-regulating additive in 
tablets. 
Microcrystalline cellulose (Emcocel™ LP200, Penwest Pharmaceuticals, 
USA), magnesium stearate (Ph. Eur.) and talc (Ph. Eur.) were also 
incorporated in the tablets.  
Triethylcitrate (Ph. Eur.), diethylphthalate (Ph. Eur.), talc, magnesium 
stearate and polysorbate 80 (Ph. Eur.) were incorporated in the coating 
solution, which was prepared using demineralized water. 
4.4. Preparation and enteric coating of matrix 
granules (I–IV) 
During the first phase of the study granules were made mechanically. 
Details of the process are given in publication I. 
Granules containing organic acids were prepared manually (II–IV). A 
20% solution in ethanol (Oy Primalco Ab, Finland) of methacrylate polymer 
(Eudragit™ S) was prepared. The Eudragit™ S was mixed slowly into the 
ethanol and the solution was stirred magnetically for 2 hours. Dry 
substances were sieved through a 1.18-mm sieve. Ibuprofen was mixed with 
the various combinations of diluents. Powder masses (each weighing 
approximately 200 g) were moistened with binder solution in a mortar and 
sieved manually through a 2.0-mm sieve. The granules were dried overnight 
at room temperature. The fraction 1.18–1.68 mm was separated by sieving. 
The percentage of enteric polymer in the dried granules was 10. The 
compositions of the granules containing organic acids are shown in Table 2. 
During the first phase of the study granules were coated using the enteric 
polymers hydroxypropylmethylcellulose acetate succinate (Aqoat™ AS-
HF) or cellulose acetate phthalate (Aquateric™). These polymers are 
soluble in water and can be used in water-based film coatings. Details of the 
coating process are given in publication I. 
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Aqoat™ AS-HF was chosen to film-coat the matrix granules containing 
organic acids on the basis of the results of the first phase of the study. 
Enteric matrix granules containing organic acids were coated using a 
fluidized-bed coater (Aeromatic Strea-1, Aeromatic AG, Switzerland) (II–
IV). The coating solution contained 10% Aqoat™ AS-HF as film former, 
3.5% triethylcitrate as plasticizer, 3% magnesium stearate as lubricant and 
83.5% demineralized water. Triethylcitrate was added to cold water and the 
solution was stirred magnetically for half an hour. The enteric-coating 
polymer was dispersed throughout the solution and magnesium stearate was 
then added. The coating solution was passed through a 0.3-mm sieve, and 
kept in an ice bath. 
 
Table 2. Compositions (%) of matrix granules containing organic acids. 
Ingredients              
Ibuprofen 60 60 60 60 60 60 60 60 60 60 60 60 60 
Calcium 
phosphate 
30 20 10 - 20 10 - 27.5 25 22.5 20 10 - 
Succinic acid (II) - 10 20 30 - - - - - - - - - 
Tartaric acid (II) - - - - 10 20 30 - - - - - - 
Citric acid       
(II–IV) 
- - - - - - - 2.5 5 7.5 10 20 30 
Eudragit™ S 100 10 10 10 10 10 10 10 10 10 10 10 10 10 
Granules were preheated for 5 minutes at an outlet temperature of 40ºC ± 
5ºC and an air-flow rate of 40 m3/h. The air-flow rate used during coating 
was 70 m3/h, the outlet temperature 40ºC ± 5ºC and the spraying pressure 1 
bar. The spraying rate was 5 g/min. Coating was continued until a 
theoretical weight increase of 20% had been achieved. Granules were dried 
after coating at the same temperature for 5 minutes, and then overnight at 
room temperature. 
21
4.5. Detection of release of drug from granules 
(I) 
Release rates of ibuprofen and furosemide from uncoated and enteric-coated 
granules containing no organic acid were detected via the gradual increase 
in pH of the dissolution medium. Details are given in publication I. 
4.6. Preparation and enteric coating of tablets 
(III–IV) 
Five granule formulations were used in the tablets (Table 3). Twelve tablet 
formulations were prepared (Table 4). The amount of the model drug 
ibuprofen in each case was 100 mg. Masses were prepared just before 
tableting. Coated granules, microcrystalline cellulose and citric acid (if 
used) were mixed in a Turbula mixer (W. A. Bachofen, Switzerland) for 5 
minutes. Magnesium stearate and talc were added and mixing continued for 
an additional 2 minutes. Tablets were compressed using concave 11-mm 
punches in a Korch EK-0 single-punch press (Erweka Apparatebau GmbH, 
Germany). The weight of each tablet was 412 mg. Compression forces were 
adjusted so that the hardness of tablets was 60–70 N, measured using a 
Schleuniger 2-E/205 tablet-hardness tester (Dr. K. Schleuniger and Co., 
Switzerland). 
 
Table 3. Compositions of cores of Aqoat™ AS-HF –enteric-coated matrix 
granules used in the tablets (%). 
Code 
Ingredients 0 2.5 5 7.5 10 
Ibuprofen 60 60 60 60 60 
Calcium 
phosphate 
30 27.5 25 22.5 20 
Citric acid 0 2.5 5 7.5 10 
Eudragit™ S 100 10 10 10 10 10 
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Aqoat™ AS-HF was used as the enteric coating for the tablets because it is 
soluble above pH 7. It was also found to be suitable as an enteric coating for 
the matrix granules used in the tablets. Tablets were enteric-coated using a 
fludized-bed coater mentioned above except that the air-flow rate was 100 
m3/h. One hundred to 200 g of tablets were coated in each case. Coating was 
continued until a theoretical weight increase of 12% had been achieved. 
 
Table 4. Compositions of uncoated tablets (%). 
Code*
Ingredients 0-
0
0-
5
0-
10
0-
11
.7
0-
13
.3
0-
15
2.
5-
10
5-
10
7.
5-
10
10
-0
10
-5
10
-1
0
Granule 0 48.5 48.5 48.5 48.5 48.5 48.5 - - - - - -
Granule 2.5 - - - - - - 48.5 - - - - -
Granule 5 - - - - - - - 48.5 - - - -
Granule 7.5 - - - - - - - - 48.5 - - -
Granule 10 - - - - - - - - - 48.5 48.5 48.5
Emcocel™ LP200 49.5 44.5 39.5 37.8 36.2 34.5 39.5 39.5 39.5 49.5 44.5 39.5
Citric acid - 5 10 11.7 13.3 15 10 10 10 - 5 10
Magnesium 
stearate 
1 1 1 1 1 1 1 1 1 1 1 1
Talc 1 1 1 1 1 1 1 1 1 1 1 1
*A code system was developed to make it easier to process the results. The first number in 
the code indicates whether granules were of code 0, 2.5, 5, 7.5 or 10, as shown in Table 3. 
The second number indicates the amount of citric acid in the tablet matrix.  
 
4.7. Dissolution tests (I–IV) 
Drug release from formulations was studied using the basket method 
described in USP 23 (apparatus: Sotax AT7, Sotax AG, Switzerland (I) or 
Dissolutest 07, Prolabo, France (II-IV)). When drug release from granules 
was studied, the amount of drug in each basket was 18 mg. When drug 
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release from tablets was studied, one tablet was placed in each basket. The 
dissolution media (at 37 ± 0.5ºC, volume 500 ml (II, III) or 900 ml (I, IV)) 
were phosphate buffers (USP 23) at pH 7.4, 6.8 and 5.8 (II–IV) or 5.0 (I). 
The speed of rotation was 100 min-1. The dissolution apparatus was 
connected to a flow-through spectrophotometer (Ultrospect II, LKB 
Biochrom Ltd., UK) via a peristaltic pump. Absorbances were recorded 
automatically at 221 nm (ibuprofen) or 274 nm (furosemide). Absorbances 
were monitored by a computer running tablet-dissolution software (TDS™, 
LKB Biochrom Ltd., UK) 
Time points at which 50% of drug had been released (t50% values) were 
calculated for the formulations from the results of the dissolution studies. 
Statistics relating to the t50% values were analysed using Student’s t-test 
relating to independent groups.  
In vitro release data were fitted to zero-order kinetics, first-order kinetics 
and a square-root of time equation using the Minsq™ program (MicroMath, 
USA). 
A gradient-dissolution study was performed using two enteric-coated 
tablet formulations containing 2.5% citric acid in the granules and 10% 
citric acid in the tablet matrix, or no citric acid in the granules and 15% 
citric acid in the tablet matrix (IV). Tablets were kept in 4 ml of 0.1 N 
hydrochloric acid (pH 1.2) for two hours. A dissolution study was then 
carried out in phosphate buffer at pH 6.8 for one hour. Testing in phosphate 
buffer at pH 7.4 followed. The dissolution apparatus and method were 
otherwise as described above.   
4.8. Bioavailability studies (I–IV) 
Thirteen groups of healthy volunteers of both sexes participated in 
randomized cross-over single-dose studies carried out in accordance with 
the recommendations of the Declaration of Helsinki (World Medical 
Assembly 1964) as revised in Edinburgh (2000). The ages of the volunteers 
ranged from 20 to 46 years, their weights from 43 to 87 kg. Before the 
studies each participant was examined physically and underwent routine 
haematological testing (Hb, ESR, S-Alat, S-Alat, S-GT, S-Drea). An 
electrocardiogram (ECG) was also obtained. The volunteers were informed 
about possible risks and adverse effects of taking the drugs, and written 
24
consent was obtained from each.  The experiments were carried out in the 
Medical Department of Orion-Pharma (I, Orion Corporation, Finland) or in 
the University of Tartu (II–IV). The study protocols had been approved by 
the Ethical Committee of Orion-Pharma (I) or the Ethical Committee of the 
University Hospital of Tartu (II–IV). 
Necessary amounts of each granule formulation studied were dispensed 
into hard gelatine capsules (size 0, Capsugel AG, Switzerland). The amount 
of ibuprofen in each capsule was 150 mg (I, II), the amount of furosemide 
60 mg. The amount of ibuprofen in each tablet was 100 mg (II, IV). One 
bioavailability study with furosemide formulations was undertaken using a 
commercial prolonged-release product for reference purposes (Lasix 
Retard™ 60 mg, Hoechst, Germany) (I). One furosemide capsule, two 
ibuprofen capsules or three ibuprofen tablets were administered to each 
subject with 200 ml of water following overnight fasting for at least 10 
hours. In one study the effect of food on bioavailability of furosemide was 
tested (I). A standard breakfast was served just before drug administration. 
In all of the experiments a standard lunch was served 4 hours after drug 
administration. The washout period between successive administrations of 
drugs was at least one week. Blood samples (10 ml) were collected from a 
forearm vein into heparinized tubes. Plasma was separated after collection 
and stored at -20°C until analysed. 
4.9. Plasma assay (I–IV) 
Ibuprofen plasma concentrations were determined by means of high-
performance liquid chromatography (HPLC) using the method described by 
Avgerinos and Hutt (1986) with slight modifications. Plasma (300 µl or 500 
µl) was measured into two test tubes. Methanol (HPLC grade, Rathburn, 
Scotland) was added (600 µl or 1 ml). The contents of the test tubes were 
mixed for 1 minute and centrifuged for 10 minutes at 4000 min-1.
Supernatants (120 µl) were measured into HPLC tubes. 
The HPLC system was equipped with a Waters Model 501 piston pump 
(USA), a Waters Model 700 or 717 Intelligent Sample Processor, a Waters 
Model 484 or 486 Tunable Absorbance Detector operated at 222 nm and a 
Waters Millenium (II–IV) or Maxima 820 (I) workstation. Sample 
separation was carried out on a µBondapak (Waters, USA) C18 reverse-
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phase silica column (3.9 x 300 mm, particle size 10 µm). The isocratic 
mobile phase was acetonitrile and 0.1 sodium acetate (35:65), the pH of 
which had been adjusted to 6.2 with glacial acetic acid. The flow rate was 2 
ml min-1. The standard curve was found to be linear (r2 > 0.996) over the 
concentration ranges 0.5–40 mg/l (I, II) and 0.3–30 mg/l (III, IV). Accuracy, 
precision, limit of quantitation, specificity and reproducibility were 
investigated as recommended by Shah et al. (1992). 
Furosemide plasma concentrations were determined by means of HPLC 
using the method described by Beerman (1982). Details of the process and 
equipment are given in publication I. 
4.10. Pharmacokinetic parameters (I–IV) 
Pharmacokinetic parameters assessed, using the Siphar™ pharmacokinetic 
data analysis program (Simed, France), were lag time in commencement of 
drug absorption (tlag), time to peak concentration (tmax), maximum plasma 
concentration (Cmax), area under the concentration time curve (AUC0-
8/12/14/24/X), mean residence time (MRT) (I, II), apparent elimination half-life 
(t1/2) (I, II) and absorption rate constant (ka) (I). The rate of absoption was also 
evaluated by means of the ratio Cmax/AUC. AUC and MRT values were 
calculated using the trapezoidal method without logarithmic transformation. 
The method of Wagner and Nelson was used to calculate the times at which 
10 and 90% had been absorbed (t10 % and t90%, I, II). Statistical analyses were 
carried out using Student`s paired t-test, the t-test for independent groups and 
the Wilcoxon or Mann-Whitney nonparametric test (for tmax values). 
4.11. In vitro/in vivo correlation (II, IV) 
Level-A in vitro/in vivo correlation was investigated using enteric-coated 
matrix granules containing 10% citric acid, 10% succinic acid, 30% succinic 
acid or no organic acid in the granule cores (II). Cumulative dissolution 
curves for each formulation at pH 6.8 were used as the in vitro parameter. 
For each volunteer the in vivo concentration versus time curve was used to 
calculate cumulative amounts absorbed at each time, using the method of 
Wagner-Nelson. Mean cumulative amounts of each formulation absorbed 
were then calculated. 
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In vitro/in vivo correlations were assessed by superimposing the in vitro 
release curve on the mean cumulative amount absorbed curve for each 
formulation, using the same set of coordinates. Correlation between mean 
values was assessed using the equation of Brocmeier et al. (1983) as 
modified by Luckow (1994), with slight alternations (Equation 1.) 
 
In the following equation t´= time in vivo, t = time in vitro, a = lag time in 
vivo, b = scale factor and c = shape factor (I). 
 
t´= a + btc (1) 
Level-A in vitro/in vivo correlation was also investigated using two enteric-
coated matrix tablets containing no citric acid in the granules and 15% citric 
acid in the tablet matrix, and 2.5% citric acid in the granules and 10% citric 
acid in the tablet matrix (IV). Cumulative dissolution curves from the 
gradient-dissolution study were used as the in vitro parameter. For both 
formulations mean in vivo concentration-versus-time curves and the method 
of Wagner-Nelson were used to calculate cumulative amounts absorbed at 
each time during the 24-hours of bioavailability testing. In vitro/in vivo 
correlations were investigated by superimposing curves. 
Level-C in vitro/in vivo correlation was investigated using time at which 
50% of the drug had dissolved (t50%) and lag time in dissolution as the in 
vitro parameters and lag time in absorption (tlag) as the in vivo parameter. 
The in vitro parameter used was plotted against the in vivo parameter and 
regression lines were calculated. Correlations were investigated at both pH 
6.8 and 7.4. 
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5. Results and discussion 
5.1. Effect of grade of enteric polymer and 
thickness of enteric coating on dissolution and 
absorption of ibuprofen and furosemide from 
enteric granules (I) 
5.1.1. Uncoated matrix granules 
The nature of the enteric polymer used in making matrix granules had no 
marked effect on absorption of drug when the granules were uncoated. 
There was no lag time in relation to absorption of ibuprofen or furosemide 
when either Eudragit™ S or Eudragit ™ L was employed in making matrix 
granules (I, Fig. 1 and 2). The pH at which disintegration took place was 6.8 
for Eudragit™ S and 6.0 for Eudragit™ L (I, Table 1). These results are 
similar to earlier findings (Spitael and Kinget 1979). In the fasting state, the 
pH in the stomach has been reported to range from 1 to 2 (Wilson et al. 
1989b). The enteric polymers mentioned above are insoluble in this pH 
range. Because there was no lag time before absorption of the model drugs, 
the latter must have diffused from the matrices. Absorption began in the 
stomach, even though neither model drug is highly soluble in acidic 
environments. Because of the diffusion of the model drugs from the matrix 
granules, the different pH level at which the enteric polymers disintegrate 
had no effect on commencement of absorption.  
Peak plasma concentrations (tmax) of ibuprofen occurred about 4.5 hours 
after administration when either enteric polymer was used to form a matrix 
(Table 5). Values for t1/2 were about 2.4 hours. With conventional 
formulation tmax has been reported to be 1.8 hours and t1/2 2.6 hours (Halsas 
et al. 1998). However, mean residence times in the study reported here were 
3 hours longer than those following administration of pure ibuprofen in 
immediate-release capsules. It is therefore obvious that the uncoated 
ibuprofen formulations in the study described here behaved as slow-release 
formulations. Such behaviour was also seen with furosemide in uncoated 
matrix granules when these were compared with a commercial prolonged-
release formulation (I, Table 3). Because drug release from the uncoated 
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formulations was immediate they were unsuitable in themselves for colon-
specific drug delivery. However, formulations of this kind could be used as 
simple slow-release formulations, e.g. for furosemide.  
5.1.2. Enteric-coated matrix granules 
In vitro release of ibuprofen was faster from Aquateric™-coated matrix 
granules than from Aqoat™ AS-HF-coated matrix granules, when Aqoat™ 
AS-HF or Eudragit™ S had been used to form the matrices (I, Fig. 3). This 
was especially evident at pH 6.8. Values for t50% at pH 6.8 for Aquateric™- 
and Aqoat™ AS-HF-coated granules were 1 hour and 3–4 hours, 
respectively. At pH 7.4 release of the model drug was also faster from 
Aquateric™-coated granules than from Aqoat™ AS-HF-coated granules. 
The pH levels at which Aquateric™- and Aqoat™ AS-HF-coated granules 
disintegrated were about 5.8 and 6.7, respectively (I, Table 1). It is therefore 
obvious that Aquateric™ does not protect granule cores for as long as 
Aqoat™ AS-HF, at the pH levels concerned. The results of the dissolution 
studies show that the nature of the enteric polymer used for film-coating 
matrix granules is more important in relation to drug release than the nature 
of the enteric polymer used to form the granule matrix. Drug release can be 
adjusted by altering the enteric polymer used for granule coating. Use of an 
enteric polymer for coating can prevent release of a drug. Once an enteric 
coating has dissolved, drug release from a matrix can begin, even though the 
matrix itself has not completely dissolved. 
Absorption of ibuprofen took place more slowly from Aqoat™ AS-HF-
coated granules than from Aquateric™-coated granules (I, Fig. 4). The lag 
time in relation to commencement of absorption was also greatest for 
Aqoat™ AS-HF-coated formulations (Table 5). It has been shown that the 
pH level at the beginning of the small intestine is about 6.6 (Evans et al. 
1988). It is therefore obvious that dissolution of Aquateric™ can commence 
as soon as granules coated with it have passed from the stomach to the small 
intestine. In the fasting state, the gastric emptying time for small particles 
such as granules, is usually brief (about an hour) (Hunter et al. 1982, 1983, 
Davis et al. 1986). From lag times relating to absorption it can also be 
concluded that granules coated with Aquateric™ are protected only in the 
stomach but that coating with Aqoat™ AS-HF can delay drug release a little 
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longer (Table 5). From the results of bioavailability testing it can also be 
concluded that the nature of the enteric polymer used for coating granules is 
more significant in relation to drug absorption than the nature of the 
polymer used to form granule matrices. When Aqoat™ AS-HF was used as 
film-coating the bioavailability of ibuprofen was very similar for matrix 
granules made with Aqoat™ AS-HF or Eudragit™ S (I, Table 4). The pH 
levels at which matrices made from the two substances disintegrate are very 
similar (I, Table 1). 
 
Table 5. Pharmacokinetic parameters of ibuprofen from uncoated and 
enteric-coated matrix granules (single-dose 300 mg, means ± SDs). 
Polymer in 
matrix* 
L S S S AS-HF AS-HF
Polymer in coating - -
A
S-
H
F
A
qu
at
er
ic
A
S-
H
F
A
qu
at
er
ic
Parameter       
tlag (h) 0.44 ± 
0.16 
0.32 ± 
0.13 
1.50 ± 
0.41 
0.59 ± 
0.40 
1.90 ± 
1.20 
0.86 ± 
0.62 
tmax (h) 4.33 ± 
0.52 
4.67 ± 
0.52 
5.00 ± 
0.62 
4.20 ± 
0.40 
4.80 ± 
0.80 
4.50 ± 
1.00 
Cmax (mg/l) 16.6 ± 
3.4 
14.7 ± 
2.0 
10.5 ± 
1.6 
16.6 ± 
3.0 
9.2 ± 
3.0 
9.5 ± 
1.1 
AUC 0-X (mg l-1h) 89.6 ± 
10.7 
88.1 ± 
17.3 
99.2 ± 
33.1 
101.0 ± 
14.1 
78.7 ± 
20.1 
82.4 ± 
12.8 
t1/2 (h) 2.37 ± 
0.47 
2.33 ± 
0.41 
- - - -
MRT (h) 6.10 ± 
0.40 
5.90 ± 
0.30 
10.70 ± 
3.90 
6.80 ± 
0.70 
10.00 ± 
1.80 
9.40 ± 
1.70 
* L = Eudragit™ L, S = Eudragit™ S, AS-HF = Aqoat™ AS-HF 
 
It was obvious that enteric-coated granules that also contain enteric 
polymers in their matrices can prevent drug liberation in the stomach. 
However, drug release from such formulations begins even in the small 
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intestine. The enteric polymers used for film-coating can start to dissolve in 
the small intestine, where the pH level exceeds 6.7. If colon-specific 
formulations are to be developed, longer lag times (3-4 hours) in relation to 
release are required.  
5.1.3. Thickness of enteric coating  
When the thickness of enteric coating with Aqoat™ AS-HF was increased, 
the rate of dissolution of the ibuprofen was reduced, especially at pH levels 
6.8 and 7.4 (I, Fig. 5). Very little drug was released at pH 5.0. In the case of 
enteric coating with Eudragit™ S the rate of release of the model drug was 
also reduced and the lag time in relation to commencement of dissolution 
increased with the thickness of the enteric coating (Ashford et al. 1993b). It 
has previously been reported that the disintegration rate of enteric-coated 
(Eudragit S and Eudragit L) tablets depends on coat thickness and that 
disintegration time was greatest when coating thickness was highest (Khan 
et al. 1999). 
With uncoated granules there was minimal lag time in relation to 
commencement of drug absorption. When the granules were enteric-coated 
using Aqoat™ AS-HF the lag time in relation to absorption was about 1.5–2 
hours (Table 5). There was no further increase in retardation of absorption 
of the model drug once the theoretical weight increase resulting from 
enteric-coating exceeded 20% (I, Fig. 6). It was therefore concluded that a 
theoretical weight increase of 20% resulting from enteric coating might be 
appropriate. It was also concluded that a colon-specific formulation could 
not be prepared simply by increasing the thickness of enteric coating of 
matrix granules. 
5.2. Effect of incorporation of an organic acid on 
dissolution and absorption of ibuprofen (II–IV) 
Following investigation of enteric-coated matrix granules that included 
enteric polymers in the granules it was concluded that neither drug 
dissolution nor absorption were sufficiently delayed if the aim was to 
develop a colon-specific formulation. It was felt it might be possible to 
delay drug dissolution and absorption further by addition of an organic acid 
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to formulations. An organic acid in matrix granules could regulate pH 
locally and retard dissolution of enteric polymers in granule cores and their 
enteric coatings. Through incorporating of an organic acid, drug release 
might be displaced from the end of the small intestine to the colon, and 
prevented in the terminal small intestine, where pH levels are higher than in 
the caecum. In this way it might be also possible to improve site 
specificities of formulations incorporating enteric polymers. 
Organic acids have been used to promote dissolution. They have been 
employed in Eudragit™ RS-film-coated multiple-unit formulations to 
modify drug release (Narisawa et al. 1994, 1996, 1997). In that study the 
aim was to increase the rate of drug release by increasing osmotic pressures 
within the formulations. It was concluded that rapid drug release after 
lengthy lag times could be achieved by means of such formulations. Organic 
acids have also been used in a capsule system involving an acid-soluble 
layer, a hydrophilic layer and an enteric-coated layer. The system is both 
pH-sensitive and time-dependent (Ishibashi et al. 1998a, b). In it, the pH 
inside the capsule decreases as the organic acid dissolves. The acid-soluble 
polymeric layer then dissolves in the acidic fluid.  
5.2.1.Effect of incorporation of an organic acid in 
granules on dissolution and absorption of ibuprofen 
from matrix granules (II) 
The dissolution rate of ibuprofen from uncoated matrix granules decreased 
when an organic acid was included in the granules. The effect was greatest 
when citric acid or succinic acid was used (II, Fig. 1 and 3). The drug 
release rate at pH 6.8 declined gradually as the amount of succinic acid 
increased. At pH 5.8, inclusion of just 10% succinic acid retarded drug 
release. Increasing the percentage of succinic acid above 10, did not reduce 
release rate further at pH 5.8. In contrast, no significant reduction in release 
rate was observed at pH 7.4 until the percentage of succinic acid was 30. 
Ibuprofen and Eudragit™ S are poorly soluble in acid. It is therefore 
obvious that addition of even a small amount of an organic acid can retard 
drug dissolution at pH 5.8. Dissolution takes place faster at 7.4 and more 
succinic acid is needed to retard drug dissolution. The results with citric acid 
were similar to those with succinic acid. When tartaric acid was included in 
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uncoated granules drug release was retarded but the effect was less marked 
than with succinic acid or citric acid (II, Fig. 2). The solubility of tartaric 
acid in aqueous solutions is good. Its pKa (2.93) is lower than the pKa-
values for citric acid (3.13) and succinic acid (4.10). It has been found that 
an organic acid with high solubility can easily diffuse from matrices and 
that it has little buffering effect (Gabr 1992).  
With uncoated granules the percentage of citric acid needed to decrease 
drug dissolution rate at pH 6.8 was 20. With enteric-coated granules the 
percentage needed to decrease drug dissolution rate at 6.8 was 10 (II, Fig. 
4). The buffering effect of citric acid in enteric-coated granules was greater 
and persisted longer than that in uncoated matrix granules. It was therefore 
obvious that dissolution of citric acid took place faster from uncoated than 
from coated granules. A short lag time in relation to commencement of drug 
dissolution at pH 6.8 was also observed when an organic acid was included 
in Aqoat™ AS-HF-coated granules. The presence of an organic acid in the 
granule core delayed dissolution of the enteric coating. 
Although incorporation of organic acids could retard drug dissolution 
from both uncoated and enteric-coated granules no effects were evident in 
bioavailability tests (II, Fig. 5 and 6). Drug absorption from uncoated 
granules containing succinic acid was similar to that from uncoated granules 
containing no organic acid (II, Fig. 5).  
The lag time in relation to commencement of drug absorption tended to 
increase when matrix granules containing organic acids were enteric coated 
(II, Table 1 and 2). However, differences were not statistically significant. 
Even though the granules were enteric-coated the inclusion of an organic 
acid had no marked effect on drug absorption. The situation in the human 
gastrointestinal tract differs from that in vitro. Mixing forces in the 
gastrointestinal tract are more powerful than those during dissolution 
studies. The organic acids used are water-soluble, which may have had an 
effect on granule disintegration.  
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5.2.2. Effect of amount and location of citric acid 
on dissolution and absorption of ibuprofen from 
tablets (III–IV)  
It was concluded that drug liberation could not be targeted solely on the 
colon by means of enteric-coated matrix granules containing organic acids. 
It was therefore decided to make multiple-unit tablets from such granules, 
and to investigate the effect of formulation on drug dissolution and 
absorption. 
The effect of varying the amount of citric acid in granules of enteric-
coated matrix tablets was investigated. Percentages of citric acid ranging 
from 0 to 10 (0.0, 2.5, 5.0, 7.5, 10.0) were incorporated in granules, with the 
percentage of citric acid in the tablet matrix remaining at 10. Formulations 
containing percentages of 0 and 10 citric acid in granules and no citric acid 
in the tablet matrix were also studied. 
When uncoated matrix tablets were studied in different phosphate buffers 
dissolution of ibuprofen was found to be gradually retarded as the amount of 
citric acid in the granules increased (III, Fig. 1). Lag times in relation to 
commencement of drug dissolution of about 30 minutes were observed at 
pH 6.8 once the percentage of citric acid in the granules exceeded 5, even 
though the tablets were uncoated. At pH 7.4 lag times of similar magnitudes 
were observed when the percentage of citric acid exceeded 7.5.  
The effects of citric acid in the granules on release rate of ibuprofen were 
similar in enteric-coated tablets and uncoated tablets. Drug release from 
enteric-coated tablets was gradually retarded and delayed as the amount of 
citric acid in the granules increased, at pH 6.8 and 7.4 (III, Fig. 2). At pH 
5.8 drug release rates were very low; only about 5% of ibuprofen had 
dissolved after 8 hours, from all formulations. Lag times in relation to 
commencement of drug dissolution increased as the amount of citric acid in 
granules increased  (Table 6). 
The effect of incorporation of citric acid in the tablet matrix was 
investigated by varying its percentage from 0 to 15, with no citric acid in the 
matrix granule cores. Formulations containing 10% citric acid in the matrix 
granule cores and 0, 5 or 10% citric acid in the tablet matrices were also 
studied. Drug dissolution from uncoated tablets in phosphate buffers at pH 
6.8 and 7.4 was retarded when 5% citric acid was included in the tablet 
matrix (III, Fig. 1). Drug dissolution rate did not decline further when the 
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percentage of acid exceeded 5%. This finding was expected because 
uncoated tablets disintegrate rapidly and the pH-regulating effect of citric 
acid in the matrix of an uncoated tablet is therefore weak. 
 
Table 6. Lag times (hours) in relation to commencement of drug dissolution 
(pH 6.8, means) and absorption (means ±SDs) in enteric-coated tablet. 
Formulations containing different amounts of citric acid in the tablet matrix 
0-0* 0-5 0-10 0-11.7 0-13.3 0-15 10-0 10-5 10-10 
Lag time 
in vitro 
0.02 0.13 0.37 1.33 0.72 1.10 0.48 0.45 1.78 
Lag time 
in vivo 
0.54 ± 
0.30 
- 1.00 ± 
0.87 
1.75 ± 
0.71 
2.00 ± 
1.85 
4.00 ± 
1.85 
0.72 ± 
0.30 
- 3.63 ± 
2.74 
Formulations containing different amounts of citric acid in the granules 
0-0 10-0 0-10 2.5-10 5-10 7.5-10 10-10   
Lag time 
in vitro 
0.02 0.48 0.37 0.82 1.22 0.93 1.78   
Lag time 
in vivo 
0.54 ± 
0.30 
0.72 ± 
0.30 
1.00 ± 
0.87 
5.13 ± 
2.32 
- - 3.63 ± 
2.74 
 
* First value = amount of citric acid in granules (%), second value = amount of citric acid 
in tablet matrix (%). 
 
Release of ibuprofen from enteric-coated tablets at pH 6.8 and 7.4 was 
gradually retarded as the percentage of citric acid in the tablet matrix 
increased from 0 to 11.7 (IV, Fig. 2). Lag times in relation to 
commencement of drug dissolution at pH 6.8 increased correspondingly 
(Table 6). Increasing the percentage of citric acid in the tablet matrix above 
11.7 did not reduce the release rate further (IV, Fig.2). It was concluded that 
when the percentage of citric acid in a tablet matrix exceeded 11.7 
degradation of the tablet matrix might be promoted. 
On the basis of the results of the gradient-dissolution study, formulations 
of these kinds are well protected in acidic environments (IV, Fig. 3). Drug 
release was also delayed at pH 6.8. 
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From the results of the in vitro dissolution studies it was concluded that 
incorporation of citric acid in granule cores can retard drug dissolution. It 
was also concluded that when the amount of citric acid in granule cores was 
increased lag times usually increased (Table 6). However, findings were 
different when the effects of incorporation of citric acid in the tablet matrix 
were investigated. Citric acid, which is water-soluble, could accelerate 
degradation of the formulation when present in certain amounts. It was also 
noted that the drug release rate was lower from an enteric-coated 
formulation containing 10% citric acid in the granule cores than from a 
formulation containing 10% citric acid in the tablet matrix (III, Fig. 2). 
Inclusion of citric acid in granules can decrease rate of dissolution for 
longer than inclusion of citric acid in the tablet matrix. 
The effects of inclusion of citric acid in granule cores on the 
bioavailability of ibuprofen was investigated using formulations containing 
0, 2.5 and 10% citric acid the in granules and 10% citric acid in the tablet 
matrix, in two separate studies. Bioavailabilities from formulations 
containing 0 or 10% citric acid in the granules and no citric acid in the tablet 
matrix were also determined. Drug absorption was delayed when citric acid 
was included in the granule cores (Fig. 2). The effect on drug absorption of 
Figure 2. Bioavailability of ibuprofen (300 mg) from enteric-coated multiple 
unit tablets containing 10% citric acid in the granules and no citric acid 
(), 2.5% citric acid in the tablet matrix () or 10% () citric acid in the 
tablet matrix. Means ± SEMs, n=8. 
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inclusion of citric acid in the granule cores was especially great when citric 
acid had also been incorporated in the tablet matrix. Lag time in relation to 
commencement of drug absorption was increased and drug absorption was 
retarded as the percentage of citric acid in the granule cores increased from 
0 to 10 (Table 6). 
The effect of location of citric acid in the tablet matrix on the 
bioavailability of ibuprofen was investigated using formulations containing 
0, 10, 11.7, 13.3 and 15% citric acid in the tablet matrix and no citric acid in 
the granules (Fig. 3). A lag time in relation to commencement of drug 
absorption was observed when the citric acid content of the tablet matrix 
equalled or exceeded 10% (Table 6). Lag times also increased as the amount 
of citric acid was increased (Fig. 3). Drug absorption rate was so slow that 
peak plasma concentrations were not achieved during the 24 hours of 
bioavailability testing when the amount of citric acid in the tablet matrix 
was over 10%.  
 
Figure 3. Bioavailability of ibuprofen (300 mg) from enteric-coated 
multiple-unit tablets containing no citric acid (x), and 10% (), 11.7% 
(), 13.3% () or 15% () citric acid in the tablet matrix and no citric 
acid in the granules. Means ± SEMs, n = 8. 
 
As previously mentioned, the time of transit through the small intestine is 3–
4 hours, regardless of formulation (Washington et al. 2001). The gastric 
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emptying time for large single units is 1–2 hours in the fasting state. It is 
therefore obvious that the lag time in relation to commencement of drug 
absorption for a formulation that is intended to be colon-specific should be 
4–6 hours. From the results of the in vivo bioavailability tests it was 
concluded that it is important to incorporate citric acid into the tablet matrix 
itself if lag times exceeding 4 hours are required (Table 6). Incorporating of 
citric acid in a tablet matrix can prevent dissolution of the enteric coating of 
a tablet. It was concluded that incorporation of between 10% and 15% citric 
acid in a tablet matrix would be appropriate for preparation of colon-specific 
formulations. With such formulations, fairly rapid absorption after lengthy 
lag times would be achievable. Inclusion of citric acid in granule cores 
allows adjustment of the rate of drug absorption, following a lag time. It is 
important for the percentage of citric acid in the granule cores to be fairly 
low, below 10. It may be even unnecessary to include citric acid in the 
granule cores. 
5.3. In vitro/in vivo correlations (II, IV) 
No level-A in vitro/in vivo correlation relating to enteric-coated matrix 
granules was observed when in vitro dissolution curves and in vivo 
cumulative absorption curves were superimposed (II, Fig. 7). The enteric 
polymers used dissolve relatively fast at pH 6.8. Drug absorption in vivo 
took place more slowly than drug release in vitro at pH 6.8 because the pH 
at the stomach during fasting is 1–2. Within this pH range dissolution of the 
enteric polymers was negligible, as would have been expected. Level-A in 
vitro/in vivo correlations could be established through use of the equation of 
Brockmeier and Luckow (II, Fig. 8). The correlations were formulation-
specific. 
Level-A in vitro/in vivo correlations relating to two enteric-coated tablet 
formulations are shown in Figure 4. Times relating to in vivo results were 
divided by 3. The in vitro dissolution curve and the in vivo cumulative 
absorption curve profiles are similar for the tablet containing 15% citric acid 
in the tablet matrix and no citric acid in granules but the lag times are 
different. A level-A in vitro/in vivo correlation might be capable of being 
established if the circumstances of the in vitro gradient dissolution study 
were modified. However, the correlation is always formulation-specific. 
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Level-C in vitro/in vivo correlations were studied in enteric-coated 
matrix tablets containing different amounts of citric acid in the tablet 
matrices or granule cores (Fig. 5). Correlation between the in vitro and in 
vivo parameters was poor. Neither the in vitro t50% value nor the in vitro lag 
time would have allowed prediction of the in vivo lag time. As discussed 
above, the rate of drug release did not decrease further when tablets 
contained more than 11.7% citric acid in the tablet matrix. However 
absorption of drug from tablets of the kinds described became delayed as 
the amount of citric acid was gradually increased.  
 
Figure 4. Level-A in vitro/in vivo correlations for enteric-coated multiple-
unit tablets containing 2.5% citric acid in the granules and 10% citric acid 
in the tablet matrix (, ), and no citric acid in the granules and 15% 
citric acid in the tablet matrix (, ). In vitro result = open symbol, in 
vivo result = closed symbol. In vivo times were divided by 3. 
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Figure 5. Level-C in vitro/in vivo correlations relating to enteric-coated 
multiple-unit tablets containing different percentages (0, 10, 11.7, 13.3, 15) 
of citric acid in the tablet matrix and no citric acid in the granules (top) or 
containing various percentages of citric acid in the granules (0, 2.5, 10) and 
10% citric acid in the tablet matrix (bottom). Tlag relating to absorption was 
used as the in vivo parameter and tlag relating to dissolution or the t50%-
value was used as the in vitro parameter. Dissolution media pH values 
were; 6.8 (, line) and 7.4 (, broken line). 
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6. Conclusions 
The main objective in relation to this study was development of an oral 
multiple-unit colon-specific formulation. The intention was to prepare a 
formulation, using enteric polymers as excipients that allowed drug 
liberation and absorption after a lag time of about 4–5 hours in the fasting 
state. The formulation developed also had to prevent drug liberation at the 
stomach. 
It was found that enteric-coated matrix granules that also contained 
enteric polymers as matrix formers are not appropriate for use in preparing 
colon-specific formulations. Drug liberation in the stomach can be 
prevented by enteric coating but after gastric emptying drug release 
occurred too rapidly, in the small intestine. The pH at which the enteric 
polymer used for coating of the granules dissolved affected the lag time in 
relation to commencement of drug absorption. Through inclusion of an 
organic acid in the granules drug dissolution can be modified in vitro. 
However, preparation of colon-specific formulations through use of enteric-
coated matrix granules that contained an organic acid as excipients proved 
impossible.   
Drug release and absorption can be targeted on the colon through use of 
enteric polymers and citric acid as excipients in multiple-unit tablets. Lag 
times of some 2–4 hours in relation to commencement absorption of 
ibuprofen can be achieved by incorporation of different amounts of citric 
acid in the tablet matrix and the granules. It is important to include citric 
acid in the tablet matrix itself if lengthy lag times are required. Percentages 
of citric acid of between 10 and 15 would be appropriate for colon-specific 
formulations. Drug release takes place after a lag time especially once the 
percentage of citric acid in the tablet matrix exceeds 10. Citric acid can be 
incorporated in the granules to adjust drug release after the lag time. It may 
be unnecessary to include citric acid in granule cores if citric acid has been 
incorporated in the tablet matrix. 
This kind of multiple-unit tablet developed is more likely than granules 
to remain entire in the upper gastrointestinal tract. Accordingly, drug 
liberation is also more likely to be prevented. If citric acid is incorporated in 
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the tablet matrix the tablet is likely to remain entire for longer. In this way 
drug release at the end of the small intestine might be prevented even 
though pH levels exceed 7. In the colon the formulation can disintegrate into 
granules. These can then distribute themselves throughout the colon. 
It was concluded that in vitro/in vivo correlation relating to the kinds of 
tablets studied was poor. It is therefore important to undertake 
bioavailability testing at all stages of development. For colon-specific 
formulations it might be possible to establish a level-A in vitro/in vivo 
correlation by adjustment of the circumstances relating to the in vitro 
gradient dissolution study.  
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